"label","instanceType","uuid:ID","id","rationale","description","name"
"","StudyDesign","5dc87f10-66f2-4283-80cf-9ec66eb2b7a5","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","Study Design 1"
